APRINOIA develops next‑generation PET imaging tracers that bind pathological tau and α‑synuclein aggregates, providing clinicians with high‑resolution, non‑invasive biomarkers for early diagnosis, disease monitoring, and patient stratification in neurodegenerative disorders. The company also creates targeted small‑molecule degraders, PROTACs, and selective antibodies to clear these aggregates, aiming to slow disease progression. By linking its diagnostic and therapeutic platforms, APRINOIA enables personalized treatment strategies and supports more efficient clinical trial designs.
Funding
$4.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurodegenerative diseases such as Alzheimer’s and Parkinson’s lack reliable, non‑invasive biomarkers and disease‑modifying therapies, making early diagnosis, patient stratification, and treatment monitoring difficult.
Solution
APRINOIA applies precision neuroscience to address these gaps by developing PET imaging tracers that bind pathological tau and α‑synuclein aggregates, delivering high‑resolution, quantifiable maps of protein deposition in the brain. These diagnostics enable clinicians to differentiate disease subtypes, assess progression, and evaluate therapeutic response. In parallel, the company creates small‑molecule degraders, proteolysis‑targeting chimeras, and selective antibodies that neutralize or clear the same aggregates, aiming to slow or halt neurodegeneration. By linking diagnostic and therapeutic platforms, APRINOIA supports personalized treatment strategies and more efficient clinical trial designs.
Target Audience
Primary customers are neurology clinics, academic research centers, and pharmaceutical partners developing disease‑modifying treatments for Alzheimer’s, Parkinson’s, and related tau or α‑synucleinopathies.
Features
- Next‑generation PET tracers ([18F]-APN-1607 florzolotau) that selectively bind tau aggregates across all tauopathies with an improved off‑target profile
- α‑synuclein PET tracer program for Parkinson’s disease and related synucleinopathies, funded by leading foundations
- Disease‑specific small‑molecule degraders (PROTAC‑style) that recruit pathological tau or α‑synuclein to the ubiquitin‑proteasome system while sparing native proteins
- Highly selective monoclonal antibody (APNmAb005) that captures toxic tau oligomers and blocks extracellular spread
- Integrated diagnostic‑therapeutic workflow that uses proprietary imaging biomarkers to select patients for targeted therapies
- Clinical‑stage programs spanning Phase 1 to Phase 3 across multiple regions (US, China, Japan)